Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 388 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... January 14, 2022 ESMO Publishes First Guidance on the Safe Use of Large Language... October 18, 2025 Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 Preparing for your COVID-19 Vaccine: What to Ask your Provider February 1, 2021 Load more HOT NEWS FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... Cancer Research UK publishes gender and ethnicity pay gap reports Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma Addressing the Challenges of Cancer Misinformation on Social Media
